Previous Close | 39.69 |
Open | 39.49 |
Bid | 39.59 x 300 |
Ask | 39.66 x 300 |
Day's Range | 39.30 - 40.40 |
52 Week Range | 37.78 - 95.02 |
Volume | |
Avg. Volume | 1,160,387 |
Market Cap | 2.651B |
Beta (5Y Monthly) | 0.12 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.15 |
Earnings Date | May 08, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 59.00 |
SAN DIEGO, April 17, 2024--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today it will report its financial results for its first quarter ended March 31, 2024, after the market close on Wednesday, May 8, 2024.
SAN DIEGO, April 10, 2024--QuidelOrtho Corporation (Nasdaq: QDEL) has added the ARK™ Fentanyl II Assay to its U.S. Vitros® XT 7600 and 5600 Integrated Systems as well as its Vitros® 4600 Chemistry System menu of assays as a MicroTip® Partnership Assay ("MPA"). This Fentanyl assay will help hospital and emergency room customers respond to the critical demand for enhanced opioid testing, allowing on-site fentanyl testing in less than 10 minutes to aid in immediate clinical decisions.
Viewing insider transactions for QuidelOrtho Corporation's ( NASDAQ:QDEL ) over the last year, we see that insiders...